2014 World Alliance Forum in San Francisco the Impact Of

Organization in Special Consultative Status with the UN Economic and Social Council

www.allianceforum.org/en

2014 World Alliance Forum in San Francisco

The Impact of Regenerative Medicine 2014

Mission Bay Conference Center at UCSF November 6 - 7, 2014

Organized by: Alliance Forum Foundation Government of Japan (Consulate General of Japan in San Francisco)

www.wafsf.org Table of Contents

Page

Greetings 3

Program 6

Speakers’ Biography 12

Masters of Ceremonies’ Biography 26

Sponsors & Major Supporting Organization 27

2 Greetings

Organization in Special Consultative Status with the UN Economic and Social Council

Greetings from George Hara Chairman of the Board, Alliance Forum Foundation

The Alliance Forum Foundation began holding its annual World Alliance Forum in the 1990s with a goal to nurture emerging technologies in the fields of IT and healthcare. Since then, the Forum has continued to be a catalyst for many new alliances among businesses, research institutions, governments, and local and international organizations that enable commercialization of innovative technologies. Last year, at the 2013 Forum, the Foundation invited leading researchers engaged in stem cell research in Japan and the US to come together in San Francisco. In the festive atmosphere of celebrating Dr. Shinya Yamanaka and his 2012 Nobel Prize in Physiology or Medicine, participants gave presentations on this new stage in the development of regenerative medicine made possible by Dr. Yamanaka's discovery of induced pluripotent stem cells (iPSC). It became clear at that Forum that this revolutionary technology will change not only our healthcare system but impact our society in the most fundamental way. At this year's Forum--The Impact of Regenerative Medicine 2014--I look forward to seeing more than forty leading researchers and business leaders from the US, Japan and other parts of the world come together to discuss current developments in clinical applications in stem cell therapeutics and share information which is vital to building social consensus towards developing stem cell research and regenerative medicine. We will also hear about exciting opportunities for investors and businesses in this burgeoning field. It is my hope that as new and existing businesses achieve success, a portion of the profits will be directed back to funding further research in the spirit of public interest capitalism so that stem cell technology may continue to make huge strides toward becoming a new economic engine of industrial growth for the benefit of all. I thank all the presenters who are coming together to make The Impact of Regenerative Medicine 2014 a valuable and important program of shared expertise and dialogue. I also want to recognize the generosity of our sponsors which made this year's Forum possible.

Ambassador George Hara Special Advisor to the Cabinet Office of the Prime Minister of Japan Chairman of the Board, Alliance Forum Foundation

Masato Watanabe Consul General of Japan in San Francisco

Message from Masato Watanabe

With the significant recent progress that has been made in the field of regenerative medicine, it is hard to believe that only a year has passed since our last meeting was held here in San Francisco. As an example of this progress, last month in Kobe, Japan, we saw the first iPS cell transplanted into a human body. This marks the first time in the world this type of surgery has taken place, and symbolizes a big leap towards the practical use of regenerative medicine. In an effort to further advance this field, the Japanese government last year legislated three acts regarding regenerative medicine, that is, the Regenerative Medicine Promotion Act, the Regenerative Medicine Safety Act, and the Medicines and Medical Devices Act. The Promotion Act has already been enacted and the other two acts will be enacted on November 25th of this year. Additionally, a new R&D management organization, Japan Agency for Medical Research and Development or A-MED, will be established in April 2015, and will serve to emulate the system of the National Institutes of Health in the United States. The Japanese government is planning to increase the R&D budget by 15%, which will be managed by A -MED. In order to further promote this innovative technology, it is essential for academia, industry and policy makers to work collaboratively. Since 1860, when Japan’s first envoy to the United States arrived, San Francisco has been characterized as a symbol of the Japan-US relationship. We sincerely hope that this forum will help to create new technologies and products for the next generation of regenerative medicine.

Masato Watanabe Consul General of Japan in San Francisco

4 Event Summary

2014 World Alliance Forum in San Francisco

Theme: The Impact of Regenerative Medicine 2014; From the Laboratory to Clinical Application

Date & Time: Thursday, November 6th, 2014 9:00 am – 5:10pm (Reception: 5:30 pm – 7:00 pm) Friday, November 7th, 2014 9:00 am – 4:45 pm (Reception: 4:45 pm – 6:00 pm)

Location: Mission Bay Conference Center at UCSF 1675 Owens Street, San Francisco, CA 94143

Organizers: Alliance Forum Foundation (AFF) Government of Japan (Consulate General of Japan in San Francisco)

Gold DEFTA PARTNERS Sponsors: Mitsui Fudosan Co., Ltd. ROHTO Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Ltd. MUFG Union Bank

Silver Astellas Pharma Inc. Sponsors: Chugai Pharmaceutical Co., Ltd.

Bronze Cellular Dynamics International Sponsors: Juventas Therapeutics, Inc. Lonza Walkersville, Inc. MEDIPOST Co., Ltd. Megakaryon Corporation Yorozu Law Group

Wi-Fi Sponsor: Lonza Walkersville, Inc.

In-Kind AlphaGraphics Sponsors: Ms. Tomoko Tsuji (IKENOBO Flower Arrangement)

Major Alliance for Regenerative Medicine (ARM) Supporting BayBio Organizations: California Institute for Regenerative Medicine CIRM California Institute for Quantitative Biosciences (QB3) Center for iPS Cell Research and Application (CiRA), Kyoto University Forum for Innovative Regenerative Medicine (FIRM) Gladstone Institutes Hara Research Foundation The Japanese Society for Regenerative Medicine (JSRM)

Supporting Alliance Forum Executive Club Organizations: Japan Bio Community (JBC) Japan Society of Northern California Japanese Chamber of Commerce of Northern California (JCCNC) Japanese University Network of the Bay Area (JUNBA) Keizai Society Student Society for Stem Cell Research (SSSCR) US-Asia Technology Management Center at Stanford University

Advisory (Chair)Mr. Hiro Ogawa, Chair, Global Advisory Committee, International Society for Stem Cell Research Board: Dr. Ken-ichi Arai, MD, PhD, Professor Emeritus and former Dean of the Institute of Medical Science, The University of Tokyo (IMSUT), Founder & Chairman, SBI Biotech, Co., Ltd. Dr. Regis Kelly, Director, California Institute for Quantitiative Biosciences (QB3) Dr. Henry A. McKinnell, Jr., former Chairman and CEO of Pfizer, Inc. Dr. Hiromitsu Nakauchi, Professor, Stanford University

5 Program (Thursday, November 6, 2014)

Day 1 – Morning: Thursday, November 6 Master of Ceremonies Elona Baum, Esq., VP, Ass. General Counsel, Coherus BioSciences, Inc. (former General Counsel & Vice President of Business Development, California Institute for Regenerative Medicine (CIRM)

8:20–9:00 Conference Registration

9:00–9:10 Opening & Welcome Remarks:

Isao “Steve” Matsuura, Conference Co-chair and Council Member, Alliance Forum Foundation The Honorable Masato Watanabe, Consul General, The Consulate General of Japan in San Francisco

THE LANDSCAPE OF STEM CELL RESEARCH AND REGENERATIVE MEDICINE Session I Regenerative Medicine 2014 Session Chair: Michael Werner

9:10–10:40 Opening Address:

"The State of the IndustryーProgress, Promise, and Challenges" Michael Werner, Executive Director, Alliance for Regenerative Medicine (ARM)

Presentations:

"My Journey Advocating for Stem Cell Research and Cures" Roman Reed, President, Roman Reed Foundation; Chairman, The Alabama Institute of Medicine; President, Sacred Cell Research Partners

“A Nonprofit Biotech's Role in Accelerating Cures through Stem Cell Research” Susan L. Solomon, JD, CEO, New York Stem Cell Foundation

"Realizing the Promise of Stem Cell Research" Arlene Chiu, PhD, Director, Office of New Research Initiatives, Beckman Research Institute, City of Hope

“Ten @ Ten & CIRM 2.0: How the Numbers Tell the Story” Jonathan Thomas, PhD, JD, Chair, Governing Board of the CIRM (Independent Citizens Oversight Committee)

“Development of Japanese Regenerative Medicine Industry” Yuzo Toda, Representative Director, Chairman, Forum for Innovative Regenerative Medi- cine

Discussion moderated by Michael Werner:

Roman Reed, Arlene Chiu, Susan L. Solomon, Jonathan Thomas,and Yuzo Toda

10:40–10:55 Coffee Break

6 Program (Thursday, November 6, 2014)

Session II Business Perspectives on the Regenerative Medicine Space Session Chair: Elona Baum 10:55–11:50 Panel Discussion moderated by Elona Baum, Esq., VP, Ass. General Counsel, Coherus BioSciences, Inc. (formerly VP, General Counsel and Business Development, CIRM):

Rahul Aras, PhD, President and Chief Executive Office, Juventas Therapeutics

Edward Lanphier, President and CEO, Sangamo BioSciences Inc.

Jay Lee, PhD, Senior Director, Business Development, MEDIPOST Co., Ltd.

Emile Nuwaysir, PhD, COO, Cellular Dynamics International

11:50–12:10 Company Presentations:

ROHTO Pharmaceutical Co., Ltd., Katsuya Hisamichi, MD, Executive Officer

Maxcyte, Inc., Madhusudan V. Peshwa, PhD, Executive Vice President, Cellular Therapies

12:10–13:00 Complimentary Lunch in the Fischer Banquet Room (1st Floor)

Day 1 - Afternoon: Thursday, November 6

Session III Frontiers of Regenerative Medicine Session Chair: Hiromitsu Nakauchi

13:00–14:15 Presentations:

“Cell Fiber Technology for Regenerative Medicine” Shoji Takeuchi, PhD, Professor, The Biohybrid Systems Laboratory, The University of Tokyo

"Realization of iPSC-organ Bud Transplantation Therapy” Takanori Takebe, MD, Associate Professor, Department of Regenerative Medicine, Yokohama City University

“From Cells to Organs – Generation of Functional Organs from Pluripotent Stem Cells” Hiromitsu Nakauchi, MD, Professor, Stanford University and The University of Tokyo

14:15–14:35 Company Presentations: Kuraray Co., Ltd., Yoko Ejiri, Microdevices Development Team “From the Nobel Prize to the Clinic: One Step Closer to iPSC- based Therapies” Lonza Walkersville, Inc., Don Paul Kovarcik, MBA, Business Development Manager, Cell Therapy, Custom Manufacturing Organization (CMO)

7 Program (Thursday, November 6, 2014)

FROM THE LABORATORY TO CLINICAL APPLICATION

Master of Ceremonies Diane Dwyer, Reporter, NBC Bay Area News 14:35–14:45 Introduction of Shinya Yamanaka: Robert Mahley, MD, PhD, Founder & President Emeritus, Gladstone Institutes; Professor of Pathology and Medicine, University of California, San Francisco 14:45–15:15 Keynote Speech:

"Recent Progress in iPS Cell Research and Application” Shinya Yamanaka, MD, PhD, Nobel Laureate, Professor and Director of the Center for iPS Cell Research and Application (CiRA), Kyoto University; Senior Investigator, L.K. Whittier Foundation Investigator in Stem Cell Biology, Gladstone Institutes; Professor, Anatomy, University of California, San Francisco

15:15–15:30 Coffee Break Session IV From the Laboratory to Clinical Application: Session Chair: Shinya Yamanaka 15:30–16:50 Presentations:

"iPS Cell Technologies : Significance and Applications to CNS Regeneration and Disease Research" Hideyuki Okano, MD, PhD, Professor, Department of Physiology, Graduate School of Medicine, Keio University; Chairman, Graduate School of Medicine, Keio University

“Pre-clinical Development of a Humanized Anti-CD47 Antibody Targeting AML Stem Cells” Ravi Majeti, MD, PhD, Assistant Professor of Medicine (Hematology), Stanford University

"Cell Sheet Tissue Engineering for Clinical Applications" Teruo Okano, PhD, Director & Professor, Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University; President, The Japanese Society for Regenerative Medicine

"Induction of immunological tolerance by T regulatory cells: from discovery to clinical application" Maria-Grazia Roncarolo, MD, Co-director, Institute for Stem Cell Biology and Regenerative Medicine; George D. Smith Professor in Stem Cell and Regenerative Medicine; Chief of the Division of Pediatric Translational and Regenerative Medicine; Professor of Pediatrics and of Medicine, Stanford University 16:50–17:20 Discussion moderated by Ravi Majeti:

Hideyuki Okano, Teruo Okano, Maria-Grazia Roncarolo, Shinya Yamanaka, and

Paul Berg, PhD, Nobel Laureate, Director Emeritus, Beckman Center and Professor Emeritus Biochemistry, Stanford University School of Medicine

17:20–17:30 Closing Remarks:

George Hara, Chairman of the Board, Alliance Forum Foundation

17:30–19:00 Cocktail Reception

8 Program (Friday, November 7, 2014)

Day 2 - Morning: Friday, November 7

8:30–9:00 Complimentary Continental Breakfast Master of Ceremonies Yoriko Kishimoto, former Mayor of Palo Alto, Board Director, Midpeninsula Regional Open Space District

9:00–9:10 Welcome:

Susumu Kaminaga, Concil member, Alliance Forum Foundation

Yoshio Yamawaki, Deputy Director-General, Research Promotion Bureau, Ministry of Education, Culture, Sports, Science and Technology (MEXT)

DEVELOPMENTS IN REGENERATIVE MEDICINE 2014

Session V Eye and Retina Session Chair: Henry Klassen

9:10–10:50 Special Speech:

“Transplantation of iPS-derived Retinal Cells” Masayo Takahashi, MD, PhD, Project Leader, Laboratory for Retinal Regeneration Research, RIKEN

Presentations:

"Embryonic Stem Cell-derived RPE for the treatment of Age-Related Macular Degeneration: The California Project to Cure Blindness" David Hinton, MD, Gavin S. Herbert Professor in Retinal Research, Professor of Pathology, Neurological Surgery and Ophthalmology, Keck School of Medicine, University of Southern California

“Human Neural Stem Cells: Potential Application for Dry Age-related Macular Degeneration” Ann Tsukamoto, PhD, Executive Vice President, Scientific and Strategic Alliances, StemCells, Inc.

“Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa” Henry Klassen, MD, PhD, Associate Professor and Director, Stem Cell & Retinal Regeneration Program, Ophthalmology, School of Medicine, University of California, Irvine 10:50–11:05 Coffee Break Master of Ceremonies Tasha A. Yorozu, Attorney at Law, Yorozu Law Group

11:05–11:20 Company Showcase:

“What It Takes to Bring the World's First iPSC-based Replacement Therapy for Patients Globally” Hardy T S Kagimoto, MD, President and CEO, Healios KK

9 Program (Friday, November 7, 2014)

Session VI Cardiovascular Session Chair: Deepak Srivastava

11:20-12:30 Special Speech:

“Regenerative Therapy for Severe Heart Failure Patients” Yoshiki Sawa, MD, PhD, Professor, Department of Cardiovascular Surgery, Graduate School of Medicine, Osaka University

Presentations:

“Cardiac Reprogramming for Regenerative Medicine” Deepak Srivastava, MD, Director and Senior Investigator, Gladstone Institute of Cardiovascular Disease; Director, Roddenberry Center for Stem Cell Biology and Medicine; Professor, Departments of Pediatrics and Biochemistry & Biophysics, University of California, San Francisco; Wilma and Adeline Pirag Distinguished Professor in Pediatric Developmental Cardiology, University of California, San Francisco

“Cardiac iPSCs for Disease Modeling and Drug Discovery” Joseph C. Wu, MD, PhD, Director, Stanford Cardiovascular Institute, Professor, Dept of Medicine/Cardiology & Radiology, Stanford University School of Medicine

12:30–13:30 Complimentary Lunch in Fischer Banquet Room (1st Floor)

Day 2 - Afternoon: Friday, November 7, 2014

A PROMISE OF LIFE SCIENCE REVOLUTION

13:30–13:35 Introduction of Mahendra Rao: Ken-ichi Arai, MD, PhD, Professor Emeritus and former Dean of the Institute of Medical Science, The University of Tokyo (IMSUT), Founder & Chairman, SBI Biotech, Co., Ltd.

13:35-14:05 Keynote Speech:

“Moving iPSC to the Clinic–Issues and Solutions” Mahendra Rao, MD, PhD, Vice-president of Regenerative Medicine, New York Stem Cell Foundation and former Director, NIH Center for Regenerative Medicine

10 Program (Friday, November 7, 2014)

Session VII Stem Cells and Translational Research Session Chair: Ken-ichi Arai

14:05–14:55 Remarks:

Ken-ichi Arai, MD, PhD, Professor Emeritus and former Dean of the Institute of Medical Science, The University of Tokyo (IMSUT), Founder & Chairman, SBI Biotech, Co., Ltd.

Presentations:

Shigetaka Asano, MD, PhD, Professor Emeritus, School of Science and Engineering, Waseda Univsersity and The Institute of Medical Science, The Tokyo University (IMSUT) Leonore A. Herzenberg, PhD, Professor, Genetics Department, Stanford University Antonio (Tony) Lee, PhD, CEO and Managing Director, MEDIPOST America, Inc.

14:55–15:15 Company Presentations:

SanBio, Inc., Keita Mori, MBA, Co-CEO, Chairman, Co-founder

Nihon Unisys, Ltd., Masao Watase, Business Development Manager

15:15–15:30 Coffee Break

Session VIII The Future of Regenerative Medicine: Five, Ten Years from Now Session Chair: Regis Kelly

15:30–16:40 Presentations:

“The Stem Cell in Context” Regis Kelly, PhD, Director, QB3, University of California, San Francisco

“Molecular Elucidation and Engineering of Stem Cell Microenvironments for Therapeutic Application” David Schaffer, PhD, Director of Stem Cell Center, University of California, Berkeley

“The Future Promise of Insights and Applications Provided by Studying Regenerative Med- icine” Thea Tlsty, PhD, Director of the Center for Translational Research in the Molecular Genetics of Cancer, University of California, San Francisco

16:40–17:00 Concluding Remark:

Mr. George Hara, Chairman of the Board, Alliance Forum Foundation

17:00–18:00 Cocktail Reception

11 Speakers (Thursday, November 6, 2014)

Steve Matsuura is Chairman of MIK International. He served as a visiting professor of Law at Osaka University (1999 - 2013) and a board director of Bank of the West (2002 - 2014). His career in international banking has taken him to London, Japan, New York, Los Angeles, and San Francisco. He served as Chairman, President, and CEO of Sanwa Bank of California from 1992-1994 and1998-2002. Mr. Matsuura joined Sanwa Bank Ltd. Head Office in Japan right after graduation from Kyoto University in 1963. Over the years he has held many positions, including General Manager of Corporate Planning, Assistant to the President & CEO, General Manager of Corporate Communications, General Manager of the New York Branch, Chairman of the Management Committee of Sanwa Securities (USA) Co., LP and Sanwa Financial Products Co., LP. He served on the Board of Directors of Sanwa Bank, Ltd., Japan and of Sanwa Bank of California (1990-1998).

Mr. Matsuura is Chairman of the Board of Directors of Japan Society since 2011. He is also on the board of numerous non-profit organizations including the Japanese Chamber of Commerce of North- Isao “Steve” ern California, International House at University of California, San Francisco-Osaka Sister City. Mr. Matsuura Matsuura has long been an advocate for strengthening US-Japan understanding. In 2007 he was Council Member named Distinguished Alumnus of the Year by I-House at UC Berkeley and in 1984 he received the Out- Alliance Forum Foundation standing Corporate Executive of the Year Award from the Asian Business League of Los Angeles. Steve Matsuura received his LLB degree from Kyoto University in 1963, his LLM degree from Kobe Universi- ty in 1969, and studied as a Visiting Scholar in 1970-71 at the University of California, Berkeley School of Law-Boalt Hall. His interests include playing the flute, singing, and playing golf.

Mr. Masato Watanabe, Consul General of Japan in San Francisco, has worked for the Ministry of For- eign Affairs in Japan since 1980. During his tenure with the Ministry, his career has primarily focused on economic cooperation and on regional affairs such as Russia and the Central and Eastern European region. He has served as Director for various divisions, which include Central and Eastern Europe, Russia and Economic Cooperation Policy. Prior to assuming his post in San Francisco, Mr. Watanabe served as Vice President of the Japan International Cooperation Agency (JICA), which aims to support the effort of developing countries for nation building, economic and social development, poverty eradi- cation, through Official Development Assistance (ODA). He has served Japanese embassies in Jakarta, Vienna, and Moscow in his diplomatic career. He holds a bachelor degree in law from the University of Tokyo.

Masato Watanabe Consul General of Japan in San Francisco

Michael Werner has more than 25 years of healthcare law, lobbying, policy development and regulatory experience in Washington. In addition to forming the Alliance for Regenerative Medi- cine and serving as its Executive Director, he is also a Partner at the law firm Holland & Knight, LLP. He focuses on issues affecting biotechnology and pharmaceutical companies, researchers and research institutions, health care investors, physicians, and patients with particular expertise in regenerative medicine. His work with clients include helping clients obtain federal funds through the appropriations and grants processes; FDA drug/biologic legislation and regulations including regulation of cell therapy and regenerative medicine products; FDA and NIH oversight of clinical trials including registries and reporting of trial results; approval and marketing of or- phan drugs; as well as conflicts of interest and other bioethics issues arising from research and uses of new technologies. Michael Werner Executive Director Alliance for Regenerative Medicine

12 A longtime health-care advocate, Ms. Solomon is a founding member and current President of NYAMR (New York- ers for the Advancement of Medical Research), is on the Executive and Nominating Committee for the Alliance for Regenerative Medicine, is a member of the Board of Directors of the Regional Plan Association of NY, and she has been a member of the Board of Directors of the Juvenile Diabetes Research Foundation, New York Chapter. Ms. Solomon was also a member of the Strategic Planning Committee of the Empire State Stem Cell Board and is currently on the Board of Directors for the Centre for Commercialization of Regenerative Medicine. In March 2008, Ms. Solomon received a New York State Women of Excellence Award from the Governor of New York. In September 2008, she received the Triumph Award from the Brooke Ellison Foundation for her work in establishing NYSCF and in December 2012, she received the Stem Cell Action Leadership Award from the Genetics Policy Institute. Prior to founding NYSCF, Ms. Solomon, an attorney and entrepreneur, spent much of her career building businesses. She established and ran Solomon Partners LLC to provide strategic management consulting to corporations, cultural institutions, foundations and non-profit organizations, and was the founding Chief Executive Officer of Sothe- Susan L. bys.com. She has served as Chairman and Chief Executive Officer of Lancit Media Productions, an Emmy award- winning children’s television production company, and as the President of Sony Worldwide Networks. Ms. Solomon

Solomon has also held executive positions at MacAndrews and Forbes Holdings and MMG Patricof and Co., and began her Chief Executive career as an attorney with Debevoise & Plimpton. Officer, Co-Founder She received her BA from New York University and her JD from Rutgers University School of Law. She has three and CEO of NYSCF sons and is married to Paul Goldberger, the Pulitzer Prize-winning writer on architecture. Picture and biographical information from the New York Stem Cell Foundation website.

After graduate school at Caltech and post-doctoral training at Washington University and Caltech, Dr. Chiu joined City of Hope as the first woman recruited to the faculty in the Division of Neurosciences. Her research, on diseases afflicting motor neurons and on the role of the extracellular matrix in synapse formation, was supported by the Na- tional Science Foundation, the National Institutes of Health (NIH) and foundations such as ALSA, the March of Dimes and the Christopher and Dana Reeve Foundation. In 1998 she joined the NIH serving as program director for Spinal Cord Injury and establishing the first program for Stem Cell Research at the National Institute for Neurological Disorders and Stroke. She was one of the founding members of the NIH Stem Cell Task Force and initiated and co- chaired a monthly meeting between NIH and the Office of Cellular, Tissue and Gene Therapies of the Food and Drug Administration. Later she joined the National Institute for Biomedical Imaging and Bioengineering as associate director overseeing the Office of Research Administration. In 2004, she received the NIH Director’s Award for her contributions to the development of stem cell research. In 2005, Dr. Chiu was recruited by the California Institute for Re- generative Medicine, the state’s stem cell agency as Director of Scientific Activities and later served as Interim Chief Arlene Y. Scientific Officer. As one of the founding members of this new agency, Dr. Chiu played a key role in the organization and execution of the review process, in developing grants administration policy and procedures, and in the formation Chiu of a comprehensive, 10 year Strategic Plan. She returned to the City of Hope in 2008 as director of the Office of New Director of the Office Research Initiatives, and Professor-in-residence in the Beckman Research Institute where she fosters new research of New Research Initia- and partnerships to bring cell-based therapies to the clinic. She currently serves on several advisory boards and has tives played a pivotal role in helping Peking University establish its first Embryonic Stem Cell Oversight Committee. Dr. Chiu continues to be a strong mentor to young scientists, especially women, and a keen supporter of responsible conduct in research.

Jonathan Thomas, Ph.D., J.D., is the Chair of the governing Board of California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM). As Chair he is responsible for helping guide the funding decisions of the agency’s 29 member Board, charged with distributing $3 billion to fund the development of stem cell therapies and cures for people in need. JT’s interest in science is a long-running one. He majored in Biology and History at Yale. As a George C. Marshall Scholar at Oxford, he then earned a PhD with a medical focus in Commonwealth History before returning to Yale Law School. His career has spanned finance, the law and politics. Before joining CIRM he was a Co-Founding Partner at Saybrook, an investment banking and private equity firm based in Santa Monica, California. His legal experience includes clerking for White House Counsel Lloyd Cutler in the last year of the Carter Administration. He has also served on a number of Boards working closely with political officials at the federal, state and local level on a variety of projects for over 25 years. Jonathan JT also has a long-standing commitment to patient advocacy, serving more than 15 years on the Board AbilityFirst, Thomas which assists children with spinal cord injuries and mental disabilities that could be targets of stem cell therapies. Chair of Governing Board of the CIRM

13 Yuzo Toda received a MSc degree in the Graduate School of Engineering from Chiba University, Japan in 1973. He has worked for over 20 years in the Fujifilm Corporation, including positions as Corporate Vice President and General Manager, Life Sciences Products Division; then Direc- tor, Senior Vice President of the Pharmaceutical Products Division and, from 2013, Senior Vice President of Regenerative Medicine. He is Director of Fujifilm Kyowa Biologics Co. Ltd and is Chair of the Forum for Innovative Regenerative Medicine, Japan.

Yuzo Toda Representative Director, Chairman, Forum for Innovative Regenerative Medicine

Elona Baum is Vice President, Associate General Counsel of Coherus BioSciences and the former General Counsel and Vice President of Business Development for the California Institute for Re- generative Medicine (CIRM). During the five years that Ms. Baum served as a member of CIRM's executive team, she built strategic relationships with leaders in the regenerative medicine field and spearheaded a number of initiatives designed to support investment in and commercialization of CIRM's early stage research programs. Prior to joining CIRM, Ms. Baum held the positions of Associate General Counsel and later Director of Regulatory Policy and Strategy at Genentech, Inc. (1996 to 2009). Prior to Genentech, she practiced law at private firms. Ms. Baum received her BA in Economics from the University of California (Cum Laude) and her JD from the University of San Francisco School of Law (Magna Cum Laude). She served as an extern for Justice John A. Arguelles, California Supreme Court Elona Baum VP Ass. General Counsel, Coherus BioSciences

Rahul Aras, Ph.D. (President and Chief Executive Officer) is the founding CEO for Juventas Therapeutics. Dr. Aras has led the Company since its inception in 2007 and has leveraged his scientific research and business experience to lead Juventas towards commercialization of its innovative therapies. Dr. Aras has successfully raised more than $38 million in venture capital and grant funding to transition Juventas’ technologies from the laboratory into mid-stage clinical trials. Prior to leading Juventas, Dr. Aras was the Director of Life Science Commercialization at Cleveland Clinic Innovations where he managed commercialization of all biotechnology and pharmaceutical related technologies developed at Cleveland Clinic. Dr. Aras has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University. Rahul Aras President and Chief Executive Officer, Juventas Therapeutics, Inc.

14 Edward Lanphier is the founder of Sangamo BioSciences, and has served as president, chief executive officer and a member of the Board of Directors since the company’s inception in 1995. He has over 30 years of experience in the pharmaceutical and biotechnology industry including senior management positions at Somatix Therapy Corporation, BioGrowth, Inc., Biotherapeu- tics, Inc., and Synergen, Inc. Before joining Synergen, he was employed by Eli Lilly and Compa- ny in the strategic business planning-biotechnology group. Mr. Lanphier currently serves on the Board of Directors of The Biotechnology Institute, is the Vice Chairman of the Board of Trustees of The Buck Institute for Research on Aging, serves on the Board and Executive Committee of the Alliance for Regenerative Medicine, is a member of the Industry Advisory Board for the Cal- ifornia Institute for Regenerative Medicine, and is on the Dean’s Advisory Board of the Univer- sity of Michigan School of Public Health. Mr. Lanphier has a B.A. in biochemistry from Knox Edward College. Lanphier President and CEO, Sanga- mo BioSciences Inc.

Jay Lee serves Medipost as a senior director in business development. Medipost is a biotech company in Korea dedicated to stem cell-based therapeutics development. He has more than 15 year experience in pharmaceutical and biotech fields specializing in business development and marketing with more than 20 licensing and investment deals over his career. Prior to joining Medipost in 2012, he worked at PacificPharma and AmorePacific as a director in marketing and business development. Jay Lee received Ph.D. in microbiology at KAIST and BSc in food engineering at Yonsei University. He holds MBA from Yonsei University.

Jay Lee Senior Director, Business Development, MEDIPOST Co., Ltd.

Dr. Nuwaysir has served as the Vice President of Research and Development, Manufacturing and Quality Systems and as the Chief Operating Officer since 2008. He is a founder and has served as director of Invenra, a Wisconsin-based early stage company developing technology for biopharmaceutical discovery, since its inception in 2011. He previously served as senior vice president of program management at Roche NimbleGen from 2007 to 2008. Prior to this, he was vice president of business development at NimbleGen Systems, Inc. from 2003 to 2007 and held various scientific and managerial roles at NimbleGen Systems, Inc. from 2000 to 2003, including molecular research and development group leader and senior manager of technical and client services. Prior to NimbleGen Systems, Inc., he held a Postdoctoral Fellowship with the National Institute of Environmental Health Sciences within the National Institutes of Emile F. Health, a postdoctoral fellowship at the University of North Carolina-Chapel Hill and a research position at EI DuPont de Nemours Stine-Haskell Laboratory. He earned his B.A. from the Uni- Nuwaysir versity of Delaware and his Ph.D. in Molecular and Environmental Toxicology with a focus in VP of Research and Develop- Oncology from the University of Wisconsin-Madison in the McArdle Laboratory for Cancer Re- ment, Manufacturing and search. Quality Systems and Chief Operating Officer , Cellular Dynamics International

15 Shoji Takeuchi received his BE, ME and Dr. Eng. in mechanical engineering from the University of Tokyo, Japan in 1995, 1997 and 2000, respectively. He is currently an associate professor in the Center for International Research on Micronano Mechatronics (CIRMM), Institute of Indus- trial Science (IIS), University of Tokyo. Since 2008, he has been a Director of the Collaborative Research Center for Bio/NanoHybrid Process at IIS. His current research interests include membrane protein chips, bottom-up tissue engineering and biohybrid MEMS. He received several awards including Young Scientists' Prize, the Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology in 2008, the JSPS prize from the Japan Society for the Promotion of Science in 2010.

Shoji Takeuchi Professor, The Biohybrid Sys- tems Laboratory, The University of Tokyo

Takanori Takebe graduated from the Yokohama City University School of Medicine in 2011, after spells as a researcher at the Scripps Research Institute Department of Chemistry (US) in 2009 and as an intern at the Columbia University Department of Transplantation Surgery (US) in 2010. The same year, he became a Research Associate at Yokohama City University. Within three years, he had published a number of exceptional pioneering works in the field of organ generation from iPS cells, proposing a new transplant approach to combat intractable organ failure – stem cell-derived organ bud transplantation therapy. Concurrently, he held a joint appointment as a researcher at Mirai Design Lab sponsored by Dentsu to establish a new field, termed ‘Advertising Medicine,’ to study the role of communication in the next-generation healthcare system. He has successfully administered more than six nationally funded projects as PI. His recent appointment as Associate Professor at age 26 made him one of the youngest facul- Takanori ty members ever in Japan. His areas of expertise are Regenerative Medicine and Advertising Medicine. Takebe Associate Professor, Yokohama City Univer- sity Graduate School of Medical Science

Hiromitsu Nakauchi obtained his M.D. from Yokohama City University School of Medicine and a Ph.D. in immunology from the University of Tokyo Graduate School of Medicine. He isolated CD8 genes during his post-doc period at the Laboratory of Prof. Leonard Herzenberg at Stan- ford University. After going back to Japan, he started working on hematopoietic stem cells in his laboratory in RIKEN. In 1994, he became Professor of Immunology at the University of Tsu- kuba where he demonstrated that a single hematopoietic stem cell could reconstitute the entire hematopoietic system, a definitive experimental proof for the “stemness” of these cells. Since April 2002, Dr. Nakauchi has been a Professor of Stem Cell Therapy at the Institute of Medical Science, The University of Tokyo (IMSUT). In 2008, he was appointed Director of newly established Center for Stem Cell Biology and Regenerative Medicine at IMSUT. Just recently, he returned to Stanford University as a faculty to continue his stem cell research at the Institute of Hiromitsu Stem Cell Biology and Regenerative Medicine. Goals of his work are to translate discoveries in Nakauchi basic research into practical medical applications. Professor, Dept. of Genetics, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University

16 Dr. Mahley is an internationally known expert on heart disease, cholesterol metabolism and Alz- heimer’s disease. He studies plasma lipoproteins and particularly apolipoprotein E (apoE), the major genetic risk factor for Alzheimer’s disease. His seminal research defined apoE’s critical role in cholesterol homeostasis, atherosclerosis, and the nervous system. These findings laid the groundwork for linking the apoE4 isoform to Alzheimer’s and neurodegeneration.

As President, Dr. Mahley oversaw the establishment and growth of the Gladstone Institutes. In 2010, after 30 years as president, he stepped down to more actively pursue his research. He recently received the Builders of Science Award from Research!America for his leadership as Gladstone’s founding director and president, guiding its growth to become one of the world’s foremost independent research institutes. Dr. Mahley is a member of the National Academy of Robert W. Sciences, the Institute of Medicine and the American Academy of Arts & Sciences.

Mahley After earning a bachelor’s degree from Maryville College, Maryville, Tenn., Dr. Mahley received Founder & President an MD and a PhD from Vanderbilt University. He completed a pathology internship at Vander- Emeritus, Gladstone bilt. He joined the National Heart, Lung, and Blood Institute at the National Institutes of Health Institutes; Professor of and eventually became head of the Comparative Atherosclerosis and Arterial Metabolism Sec- Pathology and Medicine, tion. Four years later, he was recruited to create the Gladstone Institutes. University of California, San Francisco

In 2012, Dr. Yamanaka was awarded the Nobel Prize in Physiology or Medicine for his discovery that adult somatic cells can be reprogrammed into pluripotent cells—cells that can become any type of cell. This induced pluripotent stem (iPS) cell technology represents an entirely new plat- form for fundamental studies of developmental biology. Rather than using yeast, flies, mice or other animals to create disease models, we can take iPS cells from patients with a specific disease. Because iPS cells will contain a complete set of the genes that resulted in that disease, they make it possible to create an almost-perfect disease model for studying disease development, new drugs and treatments.

In 1996, Dr. Yamanaka became an Assistant Professor at Osaka City University Medical School. In 1999, he was appointed Associate Professor at Nara Institute of Science and Technology, Shinya where he became a full professor in 2003. He took his current position as a professor at Kyoto Yamanaka University in 2004 and was appointed as a Senior Investigator at the Gladstone Institutes in Nobel Laureate, 2007. Since 2008, he has directed CiRA. Director, CiRA, Kyoto University

Hideyuki Okano received an M.D. in Physiology from Keio University in 1983, and served as a research associate at Keio University School of Medicine and Osaka University Institute for Pro- tein Research. After he obtained a Ph.D. degree from Keio University in 1988, he held a postdoctoral position at Johns Hopkins University Medical School. He was appointed full professor at Tsukuba University School of Medicine in 1994, and at Osaka University School of Medicine in 1997, and he returned to Keio University Medical School in 2001 as a full professor of Physiolo- gy. Since 2007, he has been the Dean of Keio University Graduate School of Medicine. Since 2011, he has served on the Board of Directors of the International Society of Stem Cell Research (ISSCR). He has been conducting basic research in the field of restorative medicine including neural stem cells and iPS cells, spinal cord injury, developmental genetics, and RNA binding proteins such as Musashi. Among many research areas, he is actively working on i) transplanta- tional research on spinal cord injury and strokes using iPS technologies and ii) neuroscience re- Hideyuki search using transgenic technology of non-human primates, which was originally developed by Okano his own collaborative team. His group is aiming to start the first human trials of iPSCs-based cell Chairman, Graduate School therapy for spinal cord injury in the next three years. He has received many awards and honors of Medicine including the Medal with Purple Ribbon from the Japanese Government in 2009. Keio University

17 Dr. Majeti is an Assistant Professor in the Department of Medicine, Division of Hematology, and Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. He was an undergraduate at Harvard, earned his MD and PhD from UCSF, and trained in Internal Medi- cine at Brigham and Women’s Hospital in Boston. Dr. Majeti completed his Hematology Fellow- ship at Stanford, and is a board-certified hematologist. While at Stanford, he completed postdoctoral training in the laboratory of Irving Weissman, where he investigated early human blood stem cell development and characterized acute myeloid leukemia (AML) stem cells. Dr. Majeti established his independent laboratory in 2009 with research focused on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malig- nancies, particularly acute myeloid leukemia (AML). A major focus of his lab is the identification of cell surface molecules preferentially expressed on leukemia stem cells and the development of Ravi Majeti therapeutic monoclonal antibodies targeting these proteins. Dr. Majeti is a recipient of the Bur- Assistant Professor of roughs Wellcome Fund Career Award for Medical Scientists and is a New York Stem Cell Foun- Medicine, Hematology dation Robertson Investigator. Stanford University School of Medicine

Dr. Okano is currently Director of the Institute of Advanced Biomedical Engineering and Science and professor at Tokyo Women’s Medical University. His research interests involve the use of intelligent biomaterials for biomedical research applications such as microdomain structured polymers, stimuli-responsive polymers, hydrogels, polymeric micelles, modulated drug release, targetable drug carriers, blood compatible polymers, cell engineering, tissue engineering, and artificial organs as well as others. His research group has succeeded in harvesting cultured cells as viable and confluent cell layers by modifying temperature-responsive polymer, poly(N- isopropylacrylamide) (PIPAAm) onto ordinary polystyrene tissue culture dish surfaces. Based on this temperature-responsive surface, they have proposed a new concept of “cell sheet engineering” which introduces an alternate path for tissue and organ regeneration, using only manipulat- ed cell sheets. Dr. Okano has held academic positions at institutions in Japan and the U.S. and is Teruo Okano the author or co-author of more than 500 peer-reviewed journal articles as well as over 250 Professor, Tokyo Women’s books and book chapters. Medical University; and President, The Japanese Society for Regenerative Medicine

Maria Grazia Roncarolo, MD, Professor of Pediatrics, recently joined the Stanford School of Medicine as Chief of the Division of Pediatric Translational and Regenerative Medicine and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine. Her efforts focus on the translation of scientific discoveries in genetic diseases and regenerative medicine into novel patient therapies, including treatments based on stem cells and gene therapy. Dr. Roncarolo, a pediatric immunolo- gist by training, spent her early career in Lyon, France, where she focused on severe inherited metabolic and immune diseases, including severe combined immunodeficiency (SCID), better known as “bubble boy disease.” Dr. Roncarolo was a key member of the team that carried out the first stem cell transplants given before birth to treat these genetic diseases. Dr. Roncarolo then worked at the DNAX Research Institute for Molecular and Cellular Biology in Palo Alto, where she contributed to the discovery of novel cytokines, studying their role in the induction of tolerance and promotion of stem cell growth and differentiation. As director of the Telethon Institute for Cell and Gene Therapy at the San Raffaele Scientific Institute in Milan, Dr. Roncarolo successfully led the first gene therapy trial for SCID patients Maria Grazia lacking adenosine deaminase (ADA), a severe life-threatening disorder. The trial is now considered the gold standard for gene therapy in inherited immune diseases. Under her direction, the Institute has been seminal in showing the Roncarolo efficacy of gene therapy for other untreatable inherited metabolic diseases and primary immunodeficiencies. Co-director, Over the course of her research on inherited immune diseases, Dr. Roncarolo also discovered a new class of T cells, Institute for Stem Cell called T regulatory type 1 cells. These cells play a key role in maintaining immune-system homeostasis by preventing Biology and autoimmune diseases and helping the immune system tolerate transplanted cells and organs. Recently, she pub- Regenerative lished in Nature Medicine new biomarkers for these T regulatory type 1 cells, which will be used to purify the cells and Medicine, Stanford to track them in patients.. In addition, she completed the first successful clinical trial using T regulatory type 1 cells to University prevent severe graft-versus-host disease in leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Dr. Roncarolo has brought many basic-science discoveries in this field to patients. She holds eight patents, with six more pending, for methods used in novel cell and gene therapies. She has published more than 280 scientific papers along with 22 book chapters, and her publications have been cited more than 19,000 times.

18 Paul Berg came to Stanford University in 1959; he chaired the Department of Biochemistry from 1969 to 1974 and served as Director of the Beckman Center for Molecular and Genetic Medicine 1985-2000. Professor Berg is one of the principal pioneers in gene splicing having initiated the recombinant DNA technology and methods to map the structure and function of DNA. For these achievements, he was awarded the Lasker Basic Science Award and the Nobel Prize in Chemistry in 1980. Berg is an elected member of the U.S. National Academy of Sciences, the French Acade- my of Science, the Royal Society (London) and the American Philosophical Society, He received the U. S. National Medal of Science in 1983. Dr. Berg’s activities in social and political issues related to genetics research have been nearly as influential as his research itself. The “Berg Letter” calling for a brief cessation in recombinant DNA experimentation led to the renowned Asilomar Conference in 1975. Dr. Berg continues to shape the public debate on stem cell research and bio- Paul Berg technology. Nobel Laureate, Director Emeritus Beck- man Center and Professor Emeritus Biochemistry, Stanford University School of Medicine

George Hara has been active in venture capital and high technology global alliances for over two decades. After founding DEFTA Partners in 1985, he became one of the most prominent Silicon Valley venture capitalists responsible for the emergence of numerous industry pioneering firms including Actuate, Borland, SCO, PictureTel, Tradex, and Zoran Corporation. Mr. Hara is internationally known as a leading edge technology capitalist and visionary architect in the field of post-computer technology. Since 2005, he has been actively involved with deploying next- generation technology in developing countries to improve their standard of living. Mr. Hara has served as Special Advisor to the Cabinet Office of the Prime Minister of Japan, Chairman of the Board for the Alliance Forum Foundation, Prime Minister’s Special Commissioner on the Tax Panel (Japan), Counselor to the Japanese Ministry of Finance, Ambassador Extraordinary and Plenipotentiary for IIMSAM Permanent Observer Mission to UN ECOSOC, and WAFUNIF Rep- George resentative Ambassador. He holds a Bachelor of Law from Keio University, Tokyo, and a Master Hara of Science from Stanford University. Ambassador; and Chairman, Alliance Forum Foundation & DEFTA PARTNERS

19 Speakers (Friday, November 7, 2014)

Susumu Kaminaga graduated from the University of Tokyo in 1969 after he studied Mechanical Engi- neering. He joined Sumitomo Precision Products Co., Ltd. (SPP), Japan and was president since June 2004 until retirement in June 2012 for eight years. He has managed various advanced technology and business development through aerospace, energy, environment and micro-nano industries. He is currently a Council Member of the Alliance Forum Foundation as well as Director of the Board at Defta Cap- ital, Inc. He has lived in Germany and U.K. in 1980s and 1990s, respectively and established strong relationship with universities, institutes and business partners in North America and Europe.

He is a Visiting Professor at the University of Hyogo, Japan and a member of Mechanical Engineering Department External Advisory Board at UC Berkeley. He is Fellow of Royal Aeronautical Society, UK, Fellow of JSME (The Japan Society of Mechanical Engineers) and a member of JSAP (The Japan Society of Applied Physics), IEE (The Institute of Electrical Engineers of Japan) and IEEE (The Institute of Elec- Susumu trical and Electronic Engineers). Kaminaga Council Member, Alliance Forum Foundation

Yoshio Yamawaki has been the Deputy Director-General, Research Promotion Bureau, Ministry of Edu- cation, Culture, Sports, Science and Technology (MEXT) since October 2013.

He joined the Science and Technology Agency in 1984 after receiving a master’s degree in Civil Engineer- ing from University of Tokyo. He has mainly worked on policy issues in science and technology including nuclear energy policy, promotion of basic sciences, human resources in science and technology. After he has studied at MIT, he worked at Permanent Mission of Japan to the International Organizations in Vi- enna, 1999-2002. He also served as a professor of the Hokkaido University, 2005-2007.

He previously served as Director, Promotion Policy Division, Research Promotion Bureau, MEXT, 2009- 2010; Director, Minister's Secretariat, MEXT, 2010-2012; Deputy Director-General, Sports and Youth Bureau, MEXT, 2012-2013. Yoshio He is now, as Deputy Director-General of Research Promotion Bureau, in charge of promotion of basic Yamawaki scientific research as well as strategic research according to national science and technology policy and Deputy Director-General, improvement of environment for research activities. He also has roles for promoting research and devel- Research Promotion Bureau, opment in the scientific fields including life sciences, information technology, nanotechnology and mate- MEXT rials.

She received her MD from Kyoto University in 1986, and her PhD from the same institution in 1992. After serving as assistant professor in the Department of Ophthalmology, Kyoto University Hospital, she moved to the Salk Institute in 1995, where she discovered the potential of stem cells as a tool for retinal therapy. She returned to Kyoto University Hospital in 1997, and since 2001 served as an associate professor at the Translational Research Center in the Kyoto University Hospital. She joined the Center for Developmental Biology (CDB), RIKEN, as a team leader of the retinal regeneration research team in 2006. Her clinical specialty is retinal disease – macular diseases and retinal hereditary diseases in particular. Her aim is to understand these diseases at a fundamental level and develop retinal regeneration therapies.

Masayo Takahashi Project Leader, Laboratory for Retinal Re- generation Research, RIKEN

20 David R. Hinton, MD, FARVO is Professor of Pathology and Ophthalmology at the Keck School of Medicine of the University of Southern California. He holds the Gavin S. Herbert Professor-

ship in Retinal Research and is Associate Dean for Vision Science at the Keck School. He received his medical degree and completed his residency in Neuropathology at the University of Toronto followed by a postdoctoral fellowship at the California Institute for Technology (Caltech). He has a long standing interest in the pathophysiology of common blinding disorders including age-related macular degeneration and proliferative vitreoretinopathy. He is particularly interested in the role of the retinal pigment epithelial (RPE) cell in normal retinal function and in these disorders. He is currently funded by the National Eye Institute (NIH) and the Cali- fornia Institute for Regenerative Medicine (CIRM). He is co-PI of a multicenter grant funded by CIRM named “The California Project to Cure Blindness” in which he is studying the use of em- David R. bryonic stem cell-derived RPE for the treatment of age-related macular degeneration. He is a Hinton founding member of the executive committee of the Beckman Initiative for Macular Research. Professor, Pathology, He has published over 300 peer-reviewed publications and is a frequent invited speaker at uni- Neurosurgery, Ophthalmology, versities and meetings, both nationally and internationally. Keck School of Medicine, University of Southern California

Ann Tsukamoto, Ph.D. has held various positions at StemCells, Inc., since joining the company in 1997. In 2013, she was appointed Executive Vice President for Scientific and Strategic Allianc- es after serving as the Company’s EVP, Research & Development. She received her Ph.D. in Mi- crobiology & Immunology at University of California, Los Angeles and did her postdoctoral work with Dr. Harold Varmus at the University of California, San Francisco, where she worked on the wnt-1 gene, a key player in the stem cell self-renewal pathway. Dr. Tsukamoto has been working in the stem cell field for 25 years. While at SyStemix, Inc. (1989 – 1997), the first stem cell company, she co-discovered the human hematopoietic stem cell and played a leading role in the launch of the clinical research program for this cell. Dr. Tsukamoto is an inventor on seven is- sued U.S. Patents of which six are related to the human hematopoietic stem cell. Under her direction at StemCells Inc., the scientific team has discovered the human central nervous system Ann stem cell and has initiate and completed early clinical studies with these cells. Tsukamoto Executive VP, Scientific & Strategic Alliances, StemCells, Inc.

Henry Klassen, MD, PhD, completed his combined doctoral program at the University of Pitts- burgh, followed by internship at the Cambridge Hospital, an affiliate of Harvard Medical School, and residency in ophthalmology at Yale Eye Center. He did a combined fellowship in medical retina and retinal transplantation research at Moorfields Eye Hospital and Institute of Ophthal- mology in London. Dr. Klassen was Director of Stem Cell Research at Children's Hospital of Or- ange County and Senior Scientist at the Singapore Eye Research Institute prior to joining the University of California, Irvine School of Medicine. Dr. Klassen's long standing research interests are focused on the application of neural regeneration strategies to diseases of the retina and optic nerve. Current efforts are focused on translational development of human retinal progenitor cells (hRPCs) as a candidate therapy for retinitis pigmentosa (RP) as part of a CIRM-funded Henry Klassen Disease Team and in collaboration with the TRND Program of NIH/NCATS. Associate Professor of Ophthalmology, University of California Irvine

21 After graduating from Kyushu University in 2002, Dr. Kagimoto established Aqumen Biophar- maceuticals KK in 2005. Dr. Kagimoto succeeded in the commercialization of his first product (ILM Blue) in September 2010 and started marketing it throughout Europe. This product ac- quired a high reputation and succeeded in setting an industry-wide standard. To date (as of June 2013), Dr. Kagimoto is the only person in Japan to have launched a university-based bioventure company by successfully overcoming the challenges of commercializing university-based technology. Such challenges are, as we know, commonly referred to as the "Valley of Death. " Dr. Ka- gimoto is the CEO and President of Healios K.K. which is expecting to conduct the very first clinical trials utilizing iPS cells, the medical technology that was awarded the Nobel Prize for Medi- cine and Physiology in 2012.

Hardy T S Dr. Kagimoto has won the honorary title of 1st Youth Economic New Star Award in East Asia, which is sponsored by the All-China Youth Federation, Development Association for Youth Kagimoto Worker and Korea-China Youth Culture Exchange Association . Chief Executive Officer & President, Healios K.K.

Dr. Yoshiki Sawa is Professor in the Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine. He earned a medical degree from Osaka University Faculty of Medicine in 1980 and joined the First Department of Surgery, Osaka University School of Medi- cine.

In 1989 he pursued further education in both the departments of cardiovascular physiology and cardiac surgery at the Max-Planck Institute in Germany. After returning to Japan, he became an assistant surgeon in the First Department of Surgery, Osaka University School of Medicine. He also served as a senior member of the medical staff and then a lecturer before he became an assistant professor in 2002. In 2006, he became Professor and Dean of the Department of Cardio- vascular Surgery at the Osaka University Graduate School of Medicine. He became Director of Yoshiki the Center for Advanced Medical Engineering and Informatics of Osaka University in 2010, Vice Chair of the Medical Innovation Promotion Office, Cabinet Secretariat in 2011, and Assistant Sawa Director of Osaka University Hospital and Director of the Medical Center for Translational Re- Professor, Department search in 2012. of Cardiovascular

Surgery, Osaka University (source: http://www.medical-excellence-japan.org/en/hospital/020/index.html) Graduate School of Medicine

Dr. Wu received his M.D. from Yale University School of Medicine. He completed his cardiology fellowship training followed by a PhD in Molecular Pharmacology at UCLA.

Dr. Wu has received numerous prestigious awards, including the Burroughs Wellcome Foundation Career Award for Medical Scientists (2007), the NIH Director’s New Innovator Award (2008), the Baxter Foundation Faculty Award (2008), the NIH Roadmap Transformative Award (2009), the AHA National Innovative Research Award (2009), the Presidential Early Career Award for Scientists and Engineers given by President Obama (2010), and the AHA Established Investigator Award (2013). Dr. Wu is a member of the Association of University Cardiologist (AUC) and American Society of Clinical Investigation (ASCI). Dr. Wu serves on the Editorial Board of Journal Clinical Investigation, Circula- tion Research, Circulation Cardiov Imaging, JACC Cardiov Imaging, Human Gene Therapy, Molecular Therapy, Journal of Nuclear Cardiology, and Stem Cell Research. Joseph C. Wu Dr. Wu has published more than 200 manuscripts. His lab uses a combination of genomics, cellular & Director, Stanford molecular biology, physiological testing, and molecular imaging technologies to better understand mo- Cardiovascular Institute lecular and pathophysiological processes. The lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are for (i) understanding cardiovascular disease mechanism, (ii) accelerate drug discovery and screening, and (iii) develop per- sonalized medicine platforms.

22 Dr. Srivastava’s research focuses on understanding the causes of heart disease and using knowledge of cardiac developmental to devise novel therapeutics for heart disease. He studies the molecular events regulating early and late developmental decisions that instruct progenitor cells to become heart cells and subsequently fashion a functioning heart. He is also applies modern genetic and stem cell technologies to model disease in human cells promise to yield new therapies. One of the genes he identi- fied has potent properties for cardioprotection and is currently in clinical trials for patients suffering ischemic damage to the heart.

Before joining Gladstone, Dr. Srivastava was a Professor in the Department of Pediatrics and Molec- ular Biology at the University of Texas Southwestern (UTSW) Medical Center in Dallas. He has received numerous honors, including endowed chairs at UTSW and UCSF and election to the American Society for Clinical Investigation, the Society for Pediatric Research and the American Academy of Deepak Arts and Sciences.

Srivastava Dr. Srivastava completed his medical training at the University of Texas Medical Branch in Galveston Director, and his residency in the pediatrics at UCSF. He did a fellowship in pediatric cardiology at the Chil- Gladstone Institutes dren’s Hospital of Harvard Medical School and a postdoctoral fellowship at the M.D. Anderson Cancer Center in Houston before joining the faculty at UTSW in 1996.

Dr. Ken-ichi Arai received his M.D. in 1967 from the University of Tokyo Faculty of Medicine, and a Ph.D. in Biochemistry in 1974 and served as an instructor in the Department of Chemistry at the Uni- versity of Tokyo’s Institute of Medical Science (IMSUT) with Dr. Yoshito Kaziro. After working as a Fellow of the Stanford University School of Medicine Department of Biochemistry with Dr. Arthur Kornberg (1977–1980), Dr. Arai served as Director in Molecular Biology of DNAX Research Institute of Molecular and Cellular Biology, U.S.A. (1981–1990), Consulting Professor for the Department of Bio- chemistry and Cancer Biology Program at Stanford University School of Medicine (1984-1990). In Ja- pan, he was a Professor of IMSUT’s Department of Molecular and Developmental Biology (1989– 2004), and also served as a Dean of IMSUT (1998–2003), and an Acting Director of Tokyo Metropoli- tan Institute of Medical Science (2003–2006). He received the Young Investigator Award (1976) from the Japanese Biochemical Society for studies on the role of GTP and polypeptide elongation factors. His experience in the US and Japan led him to establish the Asia-Pacific International Molecular Biolo- Ken-ichi Arai gy Network (A-IMBN) in 1997 and he now serves as its Founding President. Dr. Arai also served as the Professor Emeritus , member of the international advisory boards of biotechnology of many Asian countries. His specializa- The University of Tokyo tions are biochemistry, molecular biology (enzyme mechanism of DNA replication, gene expression, Institute of and signal transduction), molecular immunology, and hematology. Medical Science

Mahendra Rao received his MD (MBBS) from Bombay University in India and his PhD in De- velopmental Neurobiology from the California Institute of Technology. Internationally known for his research involving human embryonic stem cells (hESCs) and other somatic stem cells, he has worked in the stem cell field for more than twenty years with stints in academia, government and regulatory affairs and industry, and publishing more than 300 papers on stem cell research.

A founding Director of the NIH Center of Regenerative Medicine and also the Chief of the La- boratory of Stem Cell Biology at the NIH, Dr. Rao is currently the Vice President of Regenera- tive Medicine at the New York Stem Cell Foundation which has provided more than 100M dol- lars in research funding for cutting-edge research in Regenerative Medicine. He is also a co- Mahendra founder of a neural stem cell company, Q Therapeutics, based in Salt lake City (Utah) and more recently NxCell based in California. Rao Vice President, Until 2010 Dr. Rao led the Stem Cell and Regenerative Medicine division at Life Technologies, Regenerative Inc. (now Thermo Fisher Scientific). Dr. Rao also served as the Chair of the CBER (FDA) adviso- Medicine, New York ry committee (CTGTAC). He continues to work with the FDA and other regulatory authorities Stem Cell Foundation on PSC related issues, most recently as the CIRM and ISSCR liaison to the ISCT.

23 Shigetaka Asano, M.D. & D. Med. Sci., is the Professor Emeritus at the University of Tokyo. His current and honorary titles include the Guest Research Professor at the Waseda University, Visiting professor& Chairman at the department of Systemic Bio-Pathology, Faculth of Medicine at the Kobe University, and the professor Emeritus at the Waseda University.

His main Scientific achievements are discovery of neutropoietin (G-CSF)- producing human tumors, successful in vitro growth of human T- lymphocytes infiltrating human tumors, R&D and successful clinical-grade manufacturing of bio-medical agent Lenograstim( recombinant natural human G-CSF), establishment of public human bone marrow and cord blood banking system, and scientific proofs of perinatal tissue-derived allo-immune suppressive activity.

He is also known as recipient of the Erwin von Belz Prize in 1990, Nikkei BP Technology Prize in 1993, Shigetaka Award of International Biology of Hematopoiesis in 1997, The JOA Award for Gene Therapy in 1999, The Minister Prize of The Ministry of Education, Culture, Sports, Science &Technology Prize in 2004, Asano and The Okuma Memorial Award in 2013. Professor Emeritus, The University of Tokyo

Leonore A. Herzenberg trained at the Sorbonne and Pasteur Institute and has jointly run a Ge- netics Laboratory at Stanford University for the past sixty years. In over 500 peer reviewed articles, she has made seminal contributions to Genetics, Immunology and Flow Cytometry development. She is currently a Professor of Genetics and the Interdepartmental Program in Immu- nology.

Leonore Herzenberg Professor, Genetics Department, Stanford University

Dr. Antonio (Tony) Lee is the CEO and Managing Director at MEDIPOST America Inc. Prior to his appointment, Tony held the position of Associate Director, Business Development since 2011 at MEDIPOST Co., Ltd. (the Korean parent company) and has been involved in the product development, clinical trials, regulatory affairs, licensing and marketing of human Umbilical Cord Blood-derived Mesenchymal Stem Cell (hUCB-MSC) technology and products developed by MEDIPOST. Prior to joining MEDIPOST, Tony held research scientist positions in the filed of Stem Cell Biology & Regenerative Medicine in Sydney, Australia working on the pre-clinical adult stem cell transplantation project funded by the Australian National Health and Medical Research Council (NH&MRC). Tony received his PhD in Developmental and Stem Cell Biology with studies conducted at the University of Wales, Cardiff, U.K. and the University of Otago, Dunedin, New Zealand. Antonio (Tony) Lee CEO, MEDIPOST Ameri- ca Inc.

24 Dr. Regis B. Kelly is director of QB3, one of four Governor Gray Davis Institutes for Science and Innova- tion, created by the California Legislature to strengthen the academic foundation of its technology-based industries. QB3 is the only one of the four devoted exclusively to biology and to the life science industries. It is an innovation center made up of over 220 quantitative biologists at three northern California campuses (UCB, UCSC & UCSF) converting its discoveries into practical benefits for society. From 2000 to 2004, Dr. Kelly served as executive vice-chancellor at the University of California, San Fran- cisco, where his major responsibility was the new Mission Bay campus. This campus is the center of academic planning for a 300 acre public/private biomedical research park. From 1995 to 2000, Dr. Kelly served as chair of the Department of Biochemistry and Biophysics at UCSF; from 1988 to 1995, he was director of UCSF’s Cell Biology Graduate Program; and from 1992 to 2000, he was director of the Hormone Research Institute at UCSF. He has published extensively in the areas of cell Regis B. and neurobiology and remains a professor emeritus of the Department of Biochemistry and Biophysics. Dr. Kelly received his undergraduate degree in physics from the University of Edinburgh in Scotland in Kelly 1961 and his PhD in biophysics from the California Institute of Technology in 1967. Following a post- Director, doctoral fellowship at Stanford, Dr. Kelly was an instructor in the Department of Neurobiology at Harvard. California He is chairman emeritus of the Bay Area Scientific Innovation Consortium (BASIC), is on the Malaysian Institute for Prime Minister’s Biotechnology Advisory Panel, and is on the boards of the Scleroderma Foundation, the Quantitative San Francisco Mayor’s Biotechnology Advisory Group, and the ChinaSF Program, among others. He is also Biosciences (QB3) a general partner of the venture fund Mission Bay Capital. In November 2011, Dr. Kelly was inducted into the Bay Area Business Hall of Fame by the Bay Area Coun- cil. He has also received other awards for his support of entrepreneurship.

Thea Tlsty, PhD, is a Professor in the Department of Pathology and founding Director of the Program in Cell Cycling and Signaling in the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, CA. She received her Ph.D. from Washington University and trained at Stan- ford University before she was recruited to the University of North Carolina as Assistant Professor of Pa- thology and Member of the UNC Lineberger Comprehensive Cancer Center. In 1994 she joined the faculty at UCSF where she is currently Director of the Center for Translational Research in the Molecular Genetics of Cancer. She also serves as an Avon Scholar and a Komen Scholar for each Foundation studying breast cancer research and regularly provides counsel to the National Institutes of Health. Additionally, her work has been featured in several public forums including the San Francisco Exploratorium. Dr. Tlsty studies genetic, epigenetic and functional changes involved in the earliest steps of cancer and how interactions between stromal components and epithelial cells collaborate to moderate carcinogenesis and provide novel insights into how these early molecular events fuel cancer, tumor heterogeneity and evolu-

Thea Tlsty tion. Prior work from her laboratory developed a predictive test that distinguishes women with pre-cancer Professor, Depart- lesions that will progress to invasive cancer from those that will not progress to cancer. Her laboratory has ment of Pathology also shown that the cells surrounding cancers can dramatically influence disease both through signaling and Director of the pathways and epigenetic reprogramming. Her studies evaluate primary human cells, develop recombinant Center for Transla- models of cell-cell societal interactions and apply novel information to intact human tissue for clinical use. tional Research in Most recently her laboratory discovered pluripotent cells within the adult human body that contribute to the Molecular Ge- wound healing. The study of how these cells contribute to health, aging and rejuvenative medicine is ongo- netics of Cancer, ing. UCSF

David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neu- roscience at University of California, Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. He graduated from Stanford University with a B.S. degree in Chemical Engineer- ing in 1993. Afterward, he attended Massachusetts Institute of Technology and earned his Ph.D. also in Chemical Engineering in 1998. Finally, he did a postdoctoral fellowship in the laboratory of Fred Gage at the Salk Institute for Biological Studies in La Jolla, CA before moving to UC Berkeley in 1999. At Berkeley, Dr. Schaffer applies engineering principles to enhance stem cell and gene therapy approaches for neuroregeneration, work that includes novel approaches for molecular engineering and evolution of new viral vectors as well as new technologies to investigate and control stem cell fate decisions. David Schaffer has received an NSF CAREER Award, Office of Naval Research Young David Investigator Award, Whitaker Foundation Young Investigator Award, and was named a Technology Review Top 100 Innovator. He was also awarded the Biomedical Engineering Society Rita Shaffer Schaffer Young Investigator Award in 2000, the American Chemical Society BIOT Division Young Investiga- Professor of Chemical tor Award in 2006, and was inducted into the College of Fellows of the American Institute of Medi- and Biomolecular Engi- cal and Biological Engineering in 2010. neering, Bioengineering, and Neuroscience at UC Berkeley

25 Masters of Ceremonies

Elona Baum is Vice President, Associate General Counsel of Coherus BioSciences and the former Gen- eral Counsel and Vice President of Business Development for the California Institute for Regenerative Medicine (CIRM). During the five years that Ms. Baum served as a member of CIRM's executive team, she built strategic relationships with leaders in the regenerative medicine field and spearheaded a number of initiatives designed to support investment in and commercialization of CIRM's early stage research programs. Prior to joining CIRM, Ms. Baum held the positions of Associate General Counsel and later Director of Regulatory Policy and Strategy at Genentech, Inc. (1996 to 2009). Prior to Genentech, she practiced law at private firms. Ms. Baum received her BA in Economics from the University of Cali- fornia (Cum Laude) and her JD from the University of San Francisco School of Law (Magna Cum Laude). She served as an extern for Justice John A. Arguelles, California Supreme Court Elona Baum VP, Ass. General Counsel, Coherus BioSciences

Bay Area native Diane Dwyer has more than 20 years of experience reporting the news in the Bay Area. She has covered events from the 1989 Loma Prieta earthquake and San Quentin’s death row to Barack Obama’s historic presidential inauguration and the Olympic Games in Italy & China. Diane has also been teaching at the Haas School of Business at UC Berkeley (her alma mater) for the past 5 years. She serves on the board of the International House at UC Berkeley and runs her own business called Dwyer Media Consulting.

Diane has won several awards in journalism including: Emmy, Associated Press, New York Film Festi- val and Bay Area Society of Professional Journalist awards.

She is involved with a number of non-profits in the Bay Area, including: Summit Bank Foundation in Oakland (which helps send high school students in Oakland to college), Curry Senior Center in San Francisco’s Tenderloin, Rebuilding Together Peninsula, Asian American Donor Program, Philippine Diane Dwyer International Aide, German Shepherd Rescue and several others. Reporter, She lives in the East Bay with her husband, two children and rescue dog! NBC Bay Area news

Yoriko Kishimoto is an international consultant, author and political leader. She has worked with technology executives across the Pacific negotiating partnerships and technology transfers. Prior to joining the Midpeninsula Regional Open Space District, Yoriko Kishimoto was a member of the Palo Alto City Council where she promoted walkable communities, open government, high environmental standards, and fiscal responsibility. She became Mayor in 2007 and played a leadership role to “build a green economy through innovation” by convening many public-private collaborations. In addition to her work in the City of Palo Alto, Ms. Kishimoto also served on the boards of Hidden Villa, the Bay Area Air Quality Management District, and the Valley Transportation Authority. She attended Wesleyan Univer- sity where she earned her Bachelor of Arts degree in East Asian Studies. She earned her Masters in Business Administration from Stanford University. Yoriko Kishimoto Former Mayor, City of Palo Alto

Tasha Yorozu, founder and President of Yorozu Law Group, has been serving domestic and multi- national corporate clients for over 15 years. With a dedicated team of lawyers and staff, Yorozu Law Group specializes in commercial transactions, tax strategy, M&A, strategic alliances, technology/media licensing, and employment law. Ms. Yorozu frequently advises corporations and their in-house counsel on strategies to achieve business goals while minimizing taxes and legal risk.

Growing up in the Kyoto area and having lived in the US for most of her professional life, Ms. Yorozu is perfectly positioned to serve as outside general counsel to Japanese corporations doing business in the US. Her effectiveness in strategizing and negotiating deals for her clients stems from her ability to seamlessly navigate between Japanese and US corporate cultures, social mores, languages, and legal frameworks.

Tasha A. Yorozu When she is not working, Ms. Yorozu enjoys competing in triathlons with the family. Her goal in 2014 Attorney at Law, is to beat her 9 year old son and 13 year old daughter in sprint distance triathlons, while cheering on her Yorozu Law Group husband in his goal to complete a half Ironman.

26 Sponsors

30 Major Supporting Organizations

Hara Research Foundation

In-kind Sponsors

Ms. Tomoko Tsuji (IKENOBO flower Arrangement)

31 Tokyo Office San Francisco Office Mitsui 2nd Annex 7th Floor 111 Pine Street, Suite 1410 Nihonbashiアライアンス・フォーラム財団 Hongoku-cho 4-4-20 San Francisco, CA 94111 Chuo-ku Tokyo, Japan 103-0021 Tel: +1-415-433-7118 Tel: 03-6225-2795インフォメーション, Fax: 03-6225-2791 Fax:vo +1 l.3-415-433- 2264 A 501(c)(3) organization in Consultative [email protected] [email protected] Status with the UNECOSOC

History and Aims The Alliance Forum Foundation holds Special Consultative Status with the United Nations ECOSOC since 2011. Founded in 1985, AFF is a 501(c)(3) nonprofit organization based in California, USA. During the 1980’s, AFF played a significant role in helping to ease trade friction between Japan and the US in the field of high technology with support from the Japanese Ministry of Foreign Affairs, the Ministry of International Trade and Industry, as well as, the US Government. In 2000, recognizing the maturation of computer-centralized technology as the core industry driving the global economy, AFF established the following mission for its activities going forward: • Deploy next generation technology to change the world. • Support the development of new key industries through activities that nurture and commercialize promising new technologies and foster the development of human resources for a new age. • Contribute to Japan’s role as a vital actor in global development.

BOARD OF DIRECTORS George Hara (Chairman of the Board) AyaNakauchi (Managing Director, AFDP) Shingo Torii (Senior Executive Vice President, Suntory Holdings, Ltd.) Kyoko Watanabe (CFO, Director)

BOARD OF COUNCILORS Koki Ando Susumu Kaminaga Hiroshi Komiyama Koji Sasaki President & CEO, Nissin Foods Holdings Former President, Chairman of the Board, CEO and President, Sumitomo Precision Products Co., Ltd Mitsubishi Research Institute AdIn Research, Inc Yuichiro Anzai President, Japan Society for the Promotion of Masahiro Kan Kiyoshi Kurokawa Seiichi Shimada Science; Professor & Former President, Executive Director for Japan, Professor, National Graduate Former Chairman of the Board, Keio University World Bank Group Institute For Policy Studies Japan Housing Finance Agency

Monte Cassim Ichiro Kanazawa Akihiro Kuroda Toichi Takenaka Vice-Chancellor, Ritsumeikan Trust Dean, International University of President, KokuyoCo., Ltd. Chairman & CEO, Health and Welfare Takenaka Corporation Tsutomu Fuse Isao “Steve” Matsuura Former President, Yokohama City University Shigeru Katamine Chairman, MIK International Shunji Yanai President, Nagasaki University President, Masatoshi Ito Hideto Mitamura International Tribunal Founder and Chairman Emeritus, Yoshimitsu Kobayashi Former Ambassador of Japan For the Law of the Sea Seven & I Holdings President & CEO, To Zambia and New Zealand Mitsubishi Chemical Hldgs. Corporation Kunio Yamada Sumiko Iwao Atsutoshi Nishida Chairman and CEO, Professor Emeritus, Keio University Yotaro Kobayashi Chairman of the Board, Rohto PharmaceuticalsCo., Ltd. Former Chairman of the Board, Toshiba Corporation Fuji Xerox Co., Ltd.

Cooperation/ Support Post-Computer / Public Interest Alliance Forum Global Human New Industry Capitalism Development Resources Development International Organizations / Creation Division Research Division Programme Programme NGO’s in Developing Countries

AFDP initiatives and regional offices AFDP scalable approach

AF AFDP (Africa) AFDP (Asia) Combat Malnutrition (Spirulina) Business Lusaka, Dhaka, Telemedicine / Distance Learning (XVD) Economic Independence (microfinance) Advisory Zambia Bangladesh Program Against Malnutrition BRAC Kara Counseling TMSS Preparations are underway to formally establish the Global Human Resources Development Programme which aims (Zambia) (Bangladesh) to dispatch talented Japanese from the private sector to staff public interest projects in developing countries.

A long-term vision rooted in the public interest is crucial to drive the development of core technologies and create new key industries. Excessive market fundamentalism and shareholder-centrism have not only created severe inequities but also hindered the development of new key industries capable ofdriving global development. In 1999, AFFbegan aseries of forums to discuss and debate new capitalist mechanisms and in 2008, we established the PIC Research Division. In 2011, AFF started sponsoring a series oflectures at Tokyo University that would examine the negative effects of shareholder centrism, establish a PIC theoretical framework, and identify bestpractices in 2010 World Alliance Forum Tokyo Roundtable management that promote balanced and sustainable global development.

Alliance Forum Foundation Development Programme More than half the nations in the world are classified as developingcountries. Many ofthese countries faceproblems hindering their development including poverty, hunger, malnutrition, disease, and insufficient infrastructure to deliver basic education and healthcare. The Alliance Forum Foundation Development Programme (AFDP) is implementing a number of activities that aim to solve these The AFDP Scalable Model focuses on malnutrition, education and problems byharnessing thepower ofthe private sector. economic self-reliance

Distance Learning / Telemedicine Projects Spirulina Project (Africa) (Bangladesh and Zambia) This projectseeks to combat malnutrition in Africa through In 2005, AFDP’s first project began with private sector the use of Spirulina, an extremely nutritious kind of partners and the world’s largest NGO, BRAC, to microalgae. In 2010, AFDP succeeded in facilitating the develop a next-generation infrastructure to deliver import of Spirulina into Zambia for future distribution to distance learning and telemedicinein Bangladesh. This malnourished populations. AFDP is working in cooperation project established bracNet, aunique internet service with the Ministry of Health’s system of malnutrition clinics provider deploying WiMAX technology to provide a and local NGO’s on a two-year project aimed at distributing wireless internet in Bangladesh. braNet was Spirulina free of charge to the malnourished in Zambia. In highlighted by the World Bank for its unique addition, AFF is working to dispatch students and young framework that uses a portion of its profits for professionals to assist local populations in the safe and education and healthcare initiatives in rural areas. In effective distribution ofspirulina to combat malnutrition. 2010, AFDP launched a distance learning project utilizing XVD’s video compression technology that enables real-time HD distance classes at universities in Zambia. XVD will be further deployed to enhance education and healthcare in developing countries. Microfinance Professional Courses (Bangladesh) Microfinance is an effective development tool for assisting the poor to become financially independent. In 2009, AFDP together with BRAC University established an institute to educate aspiring microfinance professionals. Since its Lecturer (left) Sir inception, over 70 people have graduated from the Fazle Hasan Abed, Founder introductory course. Presently, AFDP is working to establish and Chairperson an in-depth master’s course in microfinance. of BRAC.

AFF Forums and other activities AFF annually hosts the World Alliance Forum Tokyo Roundtable and the World Alliance Forum in San Francisco as well as a variety of other international events including the AFDP-JICA Forum, a conference on development co-organized with the Japanese International Cooperation Agency (JICA). AFF also brings corporate leaders to developing countries such as Bangladesh World Alliance Forum AFF Corporate Delegation and Zambia as part of its corporate delegation activities. In Bangladesh (Japanese Embassy in Zambia)

www.allianceforum.org

33 Memo

34 Memo

35 Sponsors & Major Supporting Organizations